Lexeo Therapeutics, Inc. announced that on April 16, 2024, Bernard Davitian, director notified the company that he does not intend to stand for reelection as at the Company?s 2024 annual meeting of stockholders on June 25, 2024. Mr. Davitian?s notice not to stand for reelection is not the result of any disagreement with the Company on any matter relating to the Company?s operations, policies, or practices.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.2 USD | +3.32% |
|
-6.79% | +20.72% |
Jun. 13 | Baird Initiates Lexeo Therapeutics With Outperform Rating, $28 Price Target | MT |
Jun. 06 | HC Wainwright Initiates Lexeo Therapeutics at Buy With $22 Price Target | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.72% | 534M | |
+34.14% | 51.12B | |
-6.54% | 39.4B | |
+34.92% | 38.48B | |
+12.62% | 26.36B | |
-12.11% | 26.22B | |
-13.43% | 20.96B | |
+43.73% | 14.02B | |
+31.81% | 12.49B | |
-4.54% | 11.61B |
- Stock Market
- Equities
- LXEO Stock
- News Lexeo Therapeutics, Inc.
- Lexeo Therapeutics, Inc. Announces Not to Stand for Reelection of Bernard Davitian as Director